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Abstract
Background
To help decide when to start and when to stop pre-emptive therapy for cytomegalovirus
infection, we conducted two open-label randomized controlled trials in renal, liver and bone
marrow transplant recipients in a single centre where pre-emptive therapy is indicated if vir-
aemia exceeds 3000 genomes/ml (2520 IU/ml) of whole blood.
Methods
Patients with two consecutive viraemia episodes each below 3000 genomes/ml were ran-
domized to continue monitoring or to immediate treatment (Part A). A separate group of
patients with viral load greater than 3000 genomes/ml was randomized to stop pre-emptive
therapy when two consecutive levels less than 200 genomes/ml (168 IU/ml) or less than
3000 genomes/ml were obtained (Part B). For both parts, the primary endpoint was the
occurrence of a separate episode of viraemia requiring treatment because it was greater
than 3000 genomes/ml.
Results
In Part A, the primary endpoint was not significantly different between the two arms; 18/32
(56%) in the monitor arm had viraemia greater than 3000 genomes/ml compared to 10/27
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(37%) in the immediate treatment arm (p = 0.193). However, the time to developing an epi-
sode of viraemia greater than 3000 genomes/ml was significantly delayed among those
randomized to immediate treatment (p = 0.022). In Part B, the primary endpoint was not sig-
nificantly different between the two arms; 19/55 (35%) in the less than 200 genomes/ml
arm subsequently had viraemia greater than 3000 genomes/ml compared to 23/51 (45%)
among those randomized to stop treatment in the less than 3000 genomes/ml arm (p =
0.322). However, the duration of antiviral treatment was significantly shorter (p = 0.0012) in
those randomized to stop treatment when viraemia was less than 3000 genomes/ml.
Discussion
The results illustrate that patients have continuing risks for CMV infection with limited time
available for intervention. We see no need to alter current rules for stopping or starting pre-
emptive therapy.
Introduction
Opportunistic infection represents a significant problem after transplantation. Cytomegalovi-
rus (CMV) is the most common opportunist and may produce serious end organ disease if not
controlled by deploying antiviral drugs for prophylaxis or pre-emptive therapy.[1–3] In trans-
plant recipients with CMV infection, CMV disease occurs in those with high CMV viral loads
so regular monitoring of CMVDNA in blood (viraemia) coupled with treatment of low viral
loads is effective at preventing disease.[4–6] Indeed, end organ disease is now too uncommon
to be used as the primary end point for randomized clinical trials of antiviral drugs. Historically
at our institution, patients were given pre-emptive therapy on the basis of two consecutive pos-
itive CMV PCR results as detected by a qualitative PCR technique with a lower limit of detec-
tion of 200 genomes/ml whole blood.[7]With the introduction of real time PCR in 2003, it
became possible to incorporate quantitative data into the clinical management of individual
patients while maintaining the same lower limit of detection.[8]
Our natural history data showed that patients with CMV end organ disease had CMV
PCR viraemia ranging from 14,000 to 203 million (median 175,500) genomes/ml blood.[4,9]
The lower 95% confidence interval (CI) of the median of viral loads was 37,000 genomes/ml
blood and we aimed to initiate therapy in time to prevent CMV viral load reaching this
value. To give a margin of safety, bearing in mind the 1 day average doubling-time of CMV
[10] and the timing of sampling (twice-weekly), the protocols for patient management were
modified to initiate therapy once the viral load in blood increased above 3,000 genomes/ml.
Coincident with this policy change to real-time quantitative PCR monitoring, we established
two open-label randomized controlled trials to determine if exposure to the drugs used (gan-
ciclovir, valganciclovir or foscarnet) could be reduced further. Before 2003, all patients with
two consecutive positive CMV viral loads (including those between 200 and 3,000 genomes/
ml) received pre-emptive treatment because the previous PCR assay did not give a quantita-
tive result. Under the new policy, only those with viral loads greater than 3000 genomes/ml
would be treated. We therefore conducted a randomized controlled trial to determine
whether those patients with 'low level' viral loads (between 200 and 3,000 genomes/ml)
could be monitored as opposed to starting pre-emptive therapy immediately. In parallel, we
initiated a separate randomized controlled trial to determine whether the patients given pre-
emptive therapy because of high-level viral loads (above 3,000 genomes/ml blood) could
RCTs for CMV Pre-Emptive Therapy
PLOS ONE | DOI:10.1371/journal.pone.0163722 September 29, 2016 2 / 14
Competing Interests: The authors have declared
that no competing interests exist.
stop pre-emptive therapy earlier, potentially maximizing the benefits of therapy while mini-
mizing its risks. We chose to randomize patients to stop treatment when they had two con-
secutive blood samples with viral loads below the level of the assay cut-off (200 genomes/ml)
or two blood results below a level of 3000 genomes/ml (the level at which treatment was ini-
tiated for all). We hypothesized that, as viral loads would be decreasing in patients because
of the effect of the drugs used for pre-emptive therapy, together with a contribution from
the immune system of the patients, they may not require extended treatment once viral
loads reduced below a critical point.
These randomized controlled trials were designed from the perspective of a diagnostic virol-
ogy laboratory aiming to provide advice to our clinical colleagues on when to start and stop
pre-emptive therapy. The viral load parameters for the three transplant patient groups studied
here (bonemarrow transplant, renal transplant, liver transplant) are slightly different in that
the bone marrow patients get CMV end-organ disease at a lower level than do the solid organ
transplant recipients.[4] However, the values found soon after transplant by monitoring are
sufficiently similar to allow patients to be combined for the purposes of randomized controlled
trials, using stratification within each patient group and we have previously used this approach
to conduct a randomized controlled trial of ganciclovir versus ganciclovir/foscarnet in patients
from all three transplant groups.[7]
Materials and Methods
Patients
Patients undergoing CMV surveillance in a single institution because of allogeneic transplanta-
tion of kidney, liver or haematopoietic stem cells were studied.[8,11] Exclusions for both parts
included simultaneous transplantation of more than one organ or previous CMV viraemia or
disease. An exclusion for Part A was patients requiring pre-emptive therapy because their viral
load was greater than 3,000 genomes/ml. The eligibility criteria did not change during the
study.
Polymerase chain reaction and surveillance
Our strategy for CMV surveillance is described elsewhere.[8] Briefly, samples of whole
blood were collected twice a week from in-patients and out-patients for the first 60 days
post transplant, then once a week with the objective of monitoring CMV replication for the
first 90 days after transplantation. Further samples were collected from CMV viraemic
patients to follow replication episodes through to resolution. Whole blood was used rather
than plasma for these studies because the natural history data used to define cut-off values
was derived from analyses of whole blood. [4, 7–10] Because the CMV DNA results were
used for patient management, samples sent by clinicians were tested and reported with
some expected long durations of viraemia e.g. median 64 days (range 1–323) for D+R-
renal transplants. [8]
The real time PCRmethod used a Taqman probe and the ABI7700 thermal cycler as
described elsewhere.[12] The values of 200 and 3000 genomes/ml given here convert to 168
and 2520 international units/ml respectively using theWHO international standard.[13]
Doubling times of CMV viraemia and decline rates following therapy were calculated using
a standard exponential function.[10] The nadir viral load for each patient having a second epi-
sode was computed from the intersection of the plot of decline versus plot of recurrence of
viral load extrapolated from the linear regression fitting of the log10 viral load time plots
(decline and recurrence).
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Design of the two randomized controlled trials
Randomization employed random number tables administered by means of sequentially num-
bered sealed envelopes prepared by the first author, one set for each patient group, to allow stratifi-
cation by patient type. The randomization did not use pre-specifiedblock sizes and the allocation
ratio was 1:1. The study was implemented by medical staff in the Centre for Virology. As soon as a
PCR result indicated that a patient was potentially eligible, the result was discussedwith their
attending physician. If the patient was consideredwell enough to be approached, the study objec-
tives were explained and they were offered randomization into the appropriate study by ER,MR,
SW, TD, FM, GN, SA or AS. For those who agreed, the next numbered sealed envelope for their
patient group was opened and the indicated treatment policy followed. The drug and dose of anti-
viral drug to be given to an individual patient was at the discretion of their attending physician
(MH, J O’B, SM, GJ, or DT), but normally consisted of ganciclovir 5 mg per kilogram twice a day
or valganciclovir 900 mg twice a day. As alternatives, foscarnet at 60 mg per kilogram three times a
day, foscarnet at 90 mg per kilogram twice a day or half dose foscarnet plus half dose ganciclovir
were permitted, having previously been shown to control CMV viraemia to a similar extent as full-
dose ganciclovir.[5,7] All drug dosages given to individual patients were adjusted for renal function
according to themanufacturers’ guidelines. This study thus assessed the policy of administering
pre-emptive therapy without dictatingwhich antiviral drug should be used. Clinical staff were not
blinded to treatment assignment in this open label study, but the laboratory staff who produced
the viral loadmeasurements were. The two clinical trials are summarized below:
Part A. To determine if immediate treatment of patients with two
consecutive low levels of CMV viraemia significantly reduced the
number who subsequently developed a viral load greater than 3000
genomes/ml blood
Patients with a single viral load measurement between 200 and 3,000 genomes/ml were moni-
tored but were not treated. Those who developed a second, consecutive viral load between 200
and 3,000 genomes/ml were offered randomization to be treated immediately until two conse-
cutive blood samples without detectable CMVDNA were obtained or to only start treatment if
the viral load increased above 3000 genomes/ml. Because the availability of real-time PCR
results was novel, there was no available data to guide the sample size required. Assuming that
only 1% of those randomized to receive immediate treatment would develop a viral load greater
than 3000 genomes/ml, a study size of 72 patients had 90% power to detect an increase to 25%
among those randomized to monitor without treatment.
Part B. To determine if stopping pre-emptive therapy before viraemia
became undetectable increased the proportion of patients who
developed a second episode of viraemia above 3000 genomes/ml
Any patient with a viral loadmeasurement above 3,000 genomes/ml bloodwas treated as part of
our standard clinical management protocol. Patients were then offered randomization to stop
therapy when they had two consecutive viral loadmeasurements below 200 genomes/ml or two
consecutive viral loadmeasurements below 3,000 genomes/ml. All patients were monitored to
determine if the viral load subsequently increased above 3000 genomes/ml. The sample size cal-
culation was based on the estimate that a second episode of replication requiring pre-emptive
therapy (greater than 3000 genomes/ml) was expected in 30% of patients randomized to be
treated until they had two consecutive viral loadmeasurements below 200 genomes/ml. A study
size of 106 patients had 90% power to detect a doubling of this incidence to 60%
RCTs for CMV Pre-Emptive Therapy
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Objective and primary end-points
To define the number of patients with CMV viraemia who subsequently develop a viral load
greater than 3000 genomes/ml in each part of the study.
The primary end-point of Part A compared statistically the proportion in each arm who
developed viraemia greater than 3000 genomes/ml. The primary end-point of Part B compared
statistically the proportion in each arm who subsequently developed viraemia greater than
3000 genomes/ml.
These objectives and primary end-points did not change during the study.
Trial administration
The studies (protocol 6077) were approved by the Royal Free Hospital and Medical School
Research Ethics Committee (institutional review board) on 20 November 2002. All patients gave
informed consent for the study which was documented in writing.No children, or adults unable
to give informed consent, were recruited into the study. The sponsor was University College Lon-
don. The first patient was randomized in February 2003 and the last in December 2011. The
study was registered in June 2009 as ClinicalTrials.gov NCT00947141 when registration of non-
industry clinical trials became required, but patients had already been recruited by then. The
authors confirm that all ongoing and related trials for cytomegalovirushave been registered
before recruitment of the first patient. Patients who were excluded after randomization were
replaced. Once a patient had been randomized into Part A or Part B, they could not subsequently
be entered into the other part. Patients taking part in a randomized controlled trial of a prototype
CMV vaccine at our institution[14] were not eligible for either Part A or Part B.
The regulations governing clinical trials in the UK changed in 2005. The Medicines and
Healthcare RegulatoryAuthority provided an algorithm on their website to allow investigators
to decide which ongoing studies would require a Clinical Trials Authorization under the new
regulations. This study did not meet the criteria laid out in their algorithm and so no Clinical
Trials Authorization was sought. During a site inspection in March 2007, inspectors from the
Medicines and Healthcare RegulatoryAuthority agreed with that assessment using the algo-
rithm, but asked for a Clinical Trials Authorization to be applied for nonetheless. Conse-
quently, the study (both parts) was on hold from 20 April 2007 while the Medicines and
Healthcare RegulatoryAuthority reviewed the Clinical Trials Authorization application and
protocol. Of note, no changes were requested to the protocol, the Clinical Trials Authorization
was provided and the study restarted on 26 October 2007.
Statistical methods
Differences between viral loads were assessed by Student’s t-test. Differences betweenmedian
durations of treatment were assessed by Mann-Whitney test. Time to events employed
Kaplan-Meier analysis. Categorical analysis used Fisher’s exact test. All tests were two-sided
and p-values 0.05 were regarded as significant. SAS version 9.3 (SAS Institute Inc, Cary, NC)
was used.
Results
The disposition of all recruited patients is shown in Fig 1. The allocation of evaluable patients
to different studies and arms and their demographic characteristics are shown in Table 1. No
suspected unexpected serious adverse events were reported for any patient.
RCTs for CMV Pre-Emptive Therapy
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Fig 1. Disposition of patients in parts A and B of the study.
doi:10.1371/journal.pone.0163722.g001
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Part A. Patients with a low level of CMV infection at risk of developing a
viral load greater than 3000 genomes/ml
A total of 132 eligible patients were identified but 21 were considered by their clinicians to be
too ill to discuss the study while 39 declined to enter. After randomization, 6 patients in the
monitor arm and 7 in the immediate treatment arm were excluded. The reasons for this in the
monitor arm were: two had a previous episode of CMV viraemia, one had been started on
treatment already and three were lost to follow-up. The reasons for this in the immediate arm
were: two had multiple transplants, one had a high level CMV viraemia, one patient request
because of pill burden and three were lost to follow-up.
Part A stopped in December 2011 once recruitment to Part B was completed, because the
sponsor was unwilling to continue to support the study given the slow rate of recruitment. At
this time, 13 recruited patients had been excluded, so 59/72 (82%) of the target population had
been recruited and followed. These 59 patients were randomized to monitor (n = 32) or to be
treated immediately (n = 27) and constituted the modified intention-to-treat population for
Part A. The median [range] post-transplant day of randomization was 44.5 [10–122] in the
monitor arm and 44 [6–78] in the immediate treatment arm. The median post-transplant day
of last sample collectionwas 102 [13–595] in the monitor arm and 93 [39–651] in the immedi-
ate treatment arm.
The primary endpoint (a viral load of greater than 3000 genomes/ml) was observed in 28
patients (48%); 18/32 (56%) in the monitor arm versus 10/27 (37%) in the immediate treat-
ment arm (p = 0.1925). The time from transplant to developing the primary endpoint was sig-
nificantly longer (hazard ratio and 95% CI 2.52 (1.11, 5.73) p = 0.022) among those
randomized to immediate treatment (Fig 2). Three patients were receiving treatment at the
time their viral load increased above 3000 genomes/ml; the remaining patients in the immedi-
ate treatment arm had completed their therapy so were no longer receiving treatment when
Table 1. Demographic characteristics of evaluable patients according to the study and randomized arm they were allocated to.
Characteristic Part A Part B
Monitor Treat 2 <200 2 <3000
Number of patients 32 27 55 51
Transplant
• Kidney 12 13 28 27
• Liver 12 8 16 14
• Bone marrow 8 6 11 10
High CMV risk
• D+ R- SOT 3 2 16 17
• D- R+ BMT 2 2 3 3
Male 23 21 37 24
Female 9 6 18 27
Age
• Median 49 52 50 51.5
• Range 19–76 17–74 17–67 22–71
Race
• Caucasian 17 13 34 32
• Black 3 4 10 5
• Asian 11 8 7 8
• Hispanic 0 0 0 0
• Other 1 2 5 5
doi:10.1371/journal.pone.0163722.t001
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their viral load increased above 3000 genomes/ml. Of note, 3 patients in the immediate treat-
ment arm and 3 in the monitor arm already had a viral load greater than 3000 genomes/ml in a
blood taken at the time of randomization (although the result was not known at that time).
Removal of these 6 cases as part of an “as treated” analysis produced results that remained sta-
tistically non-significant (15/29(52%) versus 7/24(29%); p = 0.1610). All the treated patients in
Part A received ganciclovir or valganciclovir with none receiving foscarnet.
Although the study was not powered to provide results for each patient group separately, we
performed exploratory analyses to determine if there were marked differences for patients in
the high risk groups (Table 1) or for bonemarrow transplant patients. The primary endpoint
occurred in 6/28 (21%) high-risk patients compared to their prevalence in Part A (Table 1) of
9/59 (15%) patients. Bonemarrow transplant patients experienced9/28 (32%) endpoints com-
pared to their prevalence in Part A (Table 1) of 14/59 (24%) patients.
Only one patient in Part A developedCMV end-organ disease. A bonemarrow transplant
patient became PCR positive on post-transplant days 71 and 77 (both less than 3000 genomes/
ml) and so was recruited into the monitor arm of Part A. On day 102, symptoms of vomiting
prompted endoscopy. Gastric and duodenal biopsies had high CMV viral loads by PCR,
135,618 and 35,476 genomes/microgramof DNA respectively, but no inclusion bodies were
seen by histopathology or by immunostaining so a diagnosis of presumptive gastrointestinal
disease was made. None of six blood samples taken between recruitment and biopsy had a viral
load greater than 3000 genomes/ml. His viral load became undetectable after a three week
course of intravenous ganciclovir after which repeat gastric and duodenal biopsies contained
no CMVDNA detectable by PCR. He was then given prophylaxis with valaciclovir to avoid the
bonemarrow toxicity of valganciclovir. By day 200, his viral load became detectable above
3000 genomes/ml and valganciclovir, limited by bone marrow toxicity, failed to bring this to
Fig 2. Days from transplantation to reaching an endpoint of viraemia greater than 3000 genomes/ml whole
blood for patients in Part A of the study according to randomization to immediate treatment or to
monitoring of viraemia.
doi:10.1371/journal.pone.0163722.g002
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undetectable levels. After another 100 days of continuing viraemia he developed retinitis which
was confirmed by PCR from a vitreous sample. Thus, this patient had proven CMV end organ
disease almost one year post-transplant and approximately 7.5 months after randomization
into the study.
Part B. Patients at risk of developing a second episode of a viral load
above 3000 genomes/ml after therapy had been discontinued at one of
two defined viral load cut-offs
A total of 193 eligible patients were identified but 31 were considered by their clinicians to be
too ill to discuss the study while 50 declined to take part (Fig 1). 112/112 (100%) of the target
number of patients were recruited, including replacements for 6 who were excluded (see
below). Of these, 57 were randomized to stop treatment once two levels below 200 genomes/ml
had been detected and 55 patients were randomized to stop treatment once two levels below
3000 genomes/ml had been detected. After randomization, two patients in the low-level arm
and four in the high-level arm were excluded. The reasons for this in the low-level arm were:
one had multiple transplants, one patient request to avoid venepuncture. The reasons for this
in the high-level arm were: two had a previous episode of CMV viraemia, one had multiple
transplants and one did not receive the allocated drug. Thus, 55 and 51 patients formed the
modified intention-to-treat population for Part B. The median [range] post-transplant day of
randomization was 41 [5–192] in the less than 200 arm and 38 [13–165] in the less than 3000
arm. The median post-transplant day of last sample collectionwas 128 [33–649] in the less
than 200 arm and 162 [41–737] in the less than 3000 arm.
The patients were well matched, because there was no significant difference (p = 0.8) in the
peak viral load of the initial episode among patients randomized to two levels less than 200
genomes/ml (mean peak = 4.01± 0.52 log10 genomes/ml) compared to those randomized to
two levels less than 3000 genomes/ml (mean peak = 4.04 ± 0.57 log10 genomes/ml). There was
also no significant difference in the doubling time (mean 1.96 ± 1.15 days vs 1.64 ± 1.03 days;
p = 0.12) or the half-life of decline (mean 2.08 ± 1.08 days vs 2.03 ± 1.14 days; p = 0.89)
between the two groups.
The primary endpoint of a subsequent episode of viral replication greater than 3000
genomes/ml bloodwas reached in 42 patients; 19/55 (35%) randomized to two levels less than
200 genomes/ml and 23/51 (45%) randomized to two levels less than 3000 genomes/ml
(Table 2); this differencewas not statistically significant (p = 0.322); estimate of difference= 11%
(95% CI -8%, 29%). As expected, the duration of pre-emptive therapy was significantly shorter
in patients randomized to stop treatment on the basis of two consecutive PCR values below
3000 genomes/ml compared to two viral loads less than 200 genomes/ml (median days of treat-
ment 30 [range 8–121] versus 24 [7–62] p = 0.0012).
When the number of days of treatment for subsequent episodes were included, the overall
duration of pre-emptive therapy given to the two sets of patients was no longer significant
(median days of treatment 38 [8–347] versus 32 [7–392]; p = 0.33). Because each median value
Table 2. Number of patients in Part B of study with episodes of high or low level viraemia.
Randomized Arm Number of patients with episodes of viraemia Totals
High and Low High Low Neither
2 x <200 9 9 18 19 55
2 x <3000 11 12 11 17 51
Totals 20 21 29 36 106
doi:10.1371/journal.pone.0163722.t002
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had increased by 8, we suspected this was because of the expanded range of values seen, but
explored the results to ensure that patients stopping therapy earlier had not been predisposed
to have additional episodes of viraemia. The median days of treatment amongst those who
needed any subsequent treatment was 27 [range 12–308] versus 33 [10–336]; p = 0.22). Several
patients developedmore than one subsequent episode of viraemia, some with viral loads
greater than 3000 genomes/ml. The number of patients who had subsequent episodes of high
level viraemia, low level viraemia, both or neither are shown in Table 2, while the number of
such episodes is shown in Table 3. Overall, there was no difference between patients according
to their randomized arm. The recurrences of patients randomized to stop pre-emptive therapy
early appeared earlier, but the difference was not statistically significant (hazard ratio and 95%
CI 1.22 (0.65, 2.26) p = 0.53; Fig 3).
We explored potential clinico-pathological links between viral load measurements and out-
comes. The median nadir viral load was 1.25 log10 genomes/ml for those randomized to two
levels less than 200 genomes/ml, which was significantly (p = 0.03) lower than that (1.60 log10
genomes/ml) in those randomized to two levels less than 3000 genomes/ml. Among those with
second episodes above 3000 genomes/ml, there was no significant difference (p = 0.9) in the viral
Table 3. Number of episodes of viraemia experienced by patients in Part B of the study.
Randomized Arm Number of discrete episodes of viraemia per patient
High level >3000 Low level <3000
1 2 3 >3 1 2 3 >3
2 x <200 genomes/ml 16 0 1 1 18 5 1 3
2 x <3000 genomes/ml 17 2 2 2 14 5 3 0
doi:10.1371/journal.pone.0163722.t003
Fig 3. Proportion of patients experiencing a subsequent viraemic event requiring treatment according to
whether initial therapy was stopped after two levels below 3000 genomes/ml or two levels below 200
genomes/ml.
doi:10.1371/journal.pone.0163722.g003
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load of the initial peak of those randomized to two levels less than 200 genomes/ml (4.01 log10
genomes/ml) compared to those randomized to two levels less than 3000 genomes/ml (4.06
log10 genomes/ml). There was also no significant difference in doubling time (1.88 vs 1.75 days;
p = 0.6) or half-life of decline (1.94 vs 2.12 days; p = 0.18) in the two groups. However, within
each group, the median viral load of the initial peak was significantly greater than that of the sub-
sequent peak (4.61 vs 3.99; p<0.001 for those randomized to two levels less than 200 genomes/
ml and 4.74 vs 3.84 log10 genomes/ml; p = 0.015 for those randomized to two levels less than
3000 genomes/ml). All the treated patients received ganciclovir or valganciclovir except for six (2
in the less than 3000 arm and 4 in the less than 200 arm) who received foscarnet. There was no
obvious difference in the viral load parameters of those who received foscarnet.
Although the study was not powered to provide results for each patient group separately, we
performed exploratory analyses to determine if there were marked differences for patients in
the high risk groups (Table 1) or for bonemarrow transplant patients. The primary endpoint
occurred in 18/42 (43%) high-risk patients compared to their prevalence in Part B (Table 1) of
39/106 (37%) patients. Bone marrow transplant patients experienced5/42 (12%) endpoints
compared to their prevalence in Part B (Table 1) of 21/106 (20%) patients.
No patients in Part B developedCMV end organ disease.
Discussion
This manuscript describes the first assessment of a policy of when to start and when to stop
pre-emptive therapy using a randomized clinical trial design. For Part A of the study, it is clear
from Fig 2 that immediate treatment of some patients decreased their risk of having a viral
load greater than 3000 genomes/ml. However, in many cases this acted to delay, rather than to
eliminate, the patients' difficulty in controlling CMV replication. It might be argued that treat-
ment had not been given a fair chance to work in 3 patients in the immediate treatment arm of
Part A, because they already had a viral load greater than 3000 genomes/ml when they were
randomized. However, our study addressed the policy of whether or not treatment should be
given to such patients and the results illustrate that very little time is available to institute effec-
tive therapy in patients with two low level PCR results if the objective is to stop the viral load
rising above 3000 genomes/ml. In addition, 3 patients had an increase in viral load while they
were still taking ganciclovir, showing that administration of therapy does not always immedi-
ately control CMV replication in immunocompromized hosts–a phenomenon that has been
previously describedby us and others.[11,15–16] To put this in perspective, without receiving
antiviral therapy, the immune system of 14/32(44%) patients randomized to the monitor arm
managed to prevent their viral load increasing above 3000 genomes/ml, a figure which was
increased, non-significantly, to 17/27(63%) for those randomized to immediate treatment.
Based on these results, we cannot recommend that the current criteria for starting pre-emptive
therapy are changed for patients with two consecutive low level PCR results.
In Part B of the study, patients randomized to stop treatment before viraemia became unde-
tectable (below 200 genomes/ml blood) needed a significantly shorter duration of pre-emptive
therapy, so the objective of reducing exposure to antiviral drugs was achieved. However, this
potentially beneficial effect was attenuated on follow-up. Based on these results, we cannot rec-
ommend that the current criteria for stopping pre-emptive therapy are changed. Indeed, the
significantly higher nadir viral load in those given pre-emptive therapy until they had two
blood samples with CMVDNA below 3000 genomes/ml suggests that the initial infectionmay
have been inadequately treated to represent a focus from which viraemia could recur. Thus,
despite the significantly shorter initial episode of treatment, we cannot recommend that treat-
ment is stopped, as a matter of routine, at the earlier time point chosen here. However, if an
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individual patient experiences side-effects from pre-emptive therapy, then our results suggest
that stopping this once the viral load falls below 3000 genomes/ml on two occasions is likely to
have only minimal effects on the overall outcome.
All of the other measurements of viral load describedhere are consistent with those we have
reported previously, emphasizing that these represent robust viral biomarkers of the natural
history of CMV infection post transplantation in both solid organ and stem cell transplant
recipients.[4,7,8,11,12] The viral load parameters of the initial episode could not distinguish
those who were destined to have a subsequent episode of viraemia so there seems to be little
prospect of using these parameters to predict who is at future risk. However, confirmation of
the earlier observation that the peak viral load of a subsequent episode is significantly lower
than that of the initial episode is consistent with CMV infection acting as an endogenous
immunogen to stimulate the immune system.[17] This hypothesis could be tested by measur-
ing such responses directly[18] and has the potential to identify correlates of protective immu-
nity able to inform the selection of antigenic components for future prototype vaccines.
The strengths of this single centre study include the use of validated assays of CMV viral load
and detailed biomathematical analyses.Weaknesses include the relatively small sample size and
the long time required to recruit patients. Nevertheless, in the absence of any licensed new antivi-
ral drugwith activity against CMV, we believe the results are relevant to contemporarymedical
practice.We also show that, despite differences in CMV natural history,[8,19] patients from
three different transplant groups can be recruited into a single protocol provided that they meet
virologically-definedentry criteria and are stratified by organ transplanted. Overall, the results
from the two randomized controlled trials describedhere underscore the vulnerable nature of
transplant patients to CMV infection and their ongoing risks for repeat infection after an initial
episode has been treated. They emphasize that improved ways of helping the immune system to
control CMV infection are required in the way that some patients cannot control CMV replica-
tion once prophylaxis with valganciclovir has been stopped, even if given for 200 days post trans-
plant.[3] Thus, we reported on a separate cohort of patients who had reduced viraemia and need
for valganciclovir treatment post-transplant after pre-transplant administration of an investiga-
tional CMV vaccine compared to controls randomized to receive placebo.[14] Vaccines able to
induce immunity in seronegative individuals and to boost the natural immunity of seropositives
may therefore represent a better way of controlling CMV replication than comparing different
policies of pre-emptive therapy in those patients who fail to keep CMV suppressed to undetect-
able levels post-transplant.[14,20] Indeed, the natural history data presented here suggest the
additional possibility that administration of vaccine or placebo at the time of detecting a single,
low level PCR positive result post transplant represents an alternative study design to identify
vaccines able to enhance immunological control of CMV in these patients.
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